The authors of the paper would like to apologize for the following errors contained in the original paper.

1. The exact Figure 1 in the original paper has to be corrected as Figure 1 in this paper.


Figure 1 
2. References in the original paper have to be corrected by adding the following:[34]M. D. Oldfield, L. A. Bach, J. M. Forbes et al., “Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE),” Journal of Clinical Investigation, vol. 108, no. 12, pp. 1853–1863, 2001.[35]M. P. Wautier, O. Chappey, S. Corda, D. M. Stern, A. M. Schmidt, and J. L. Wautier, “Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE,” American Journal of Physiology, vol. 280, no. 5, pp. E685–E694, 2001.[36]J. Zhao,W. Shi, Y. L.Wang et al., “Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice,” American Journal of Physiology, vol. 282, no. 3, pp. L585–L593, 2002.[37]V. J. Thannickal and B. L. Fanburg, “Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor β1,” Journal of Biological Chemistry, vol. 270, no. 51, pp. 30334–30338, 1995.[38]A. Bellocq, E. Azoulay, S. Marullo et al., “Reactive oxygen and nitrogen intermediates increase transforming growth factor-β1 release from human epithelial alveolar cells through two different mechanisms,” American Journal of Respiratory Cell and Molecular Biology, vol. 21, no. 1, pp. 128–136, 1999.[39]M. H. Barcellos-Hoff and T. A. Dix, “Redox-mediated activation of latent transforming growth factor-β1,” Molecular Endocrinology, vol. 10, no. 9, pp. 1077–1083, 1996.[40]C. L. Fattman, “Apoptosis in pulmonary fibrosis: too much or not enough?” Antioxidants and Redox Signaling, vol. 10, no. 2, pp. 379–385, 2008.[41]A. Bierhaus, T. Illmer, M. Kasper et al., “Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE,” Circulation, vol. 96, no. 7, pp. 2262–2271, 1997.[42]V. Nilakantan, N. L. N. Halligan, T. K. Nguyen et al., “Post-translational modification of manganese superoxide dismutase in acutely rejecting cardiac transplants: role of inducible nitric oxide synthase,” Journal of Heart and Lung Transplantation, vol. 24, no. 10, pp. 1591–1599, 2005.[43]H. M. Lander, J. M. Tauras, J. S. Ogiste, O. Hori, R. A. Moss, and A. M. Schmidt, “Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress,” Journal of Biological Chemistry, vol. 272, no. 28, pp. 17810–17814, 1997.[44]R. J. Folz and J. D. Crapo, “Extracellular superoxide dismutase (SOD3): tissue-specific expression, genomic characterization, and computer-assisted sequence analysis of the human EC SOD gene,” Genomics, vol. 22, no. 1, pp. 162–171, 1994.[45]L. I. Wang, D. P. Miller, Y. Sai et al., “Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk,” Journal of the National Cancer Institute, vol. 93, no. 23, pp. 1818–1821, 2001.